British pharmaceutical giant GSK has made its boldest move yet to rebuild its oncology business, agreeing to acquire Nuvalent in a record $10.6 billion transaction ... The post GSK Bets $10.6 Billion on Nuvalent to Strengthen Cancer Ambitions and Challenge Industry Leaders first appeared on [your]NEWS.